Press release
Lawsuit filed for Investors in shares of Spero Therapeutics, Inc. (NASDAQ: SPRO)
An investor, who purchased shares of Spero Therapeutics, Inc. (NASDAQ: SPRO), filed a lawsuit against Spero Therapeutics, Inc over alleged violations of Federal Securities Laws.Investors who purchased shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) have certain options and for certain investors are short and strict deadlines running. Deadline: July 25, 2022. NASDAQ: SPRO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Cambridge, MA based Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
On October 28, 2021, Spero Therapeutics, Inc. announced that it had submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis (the "Tebipenem HBr NDA").
On March 31, 2022, Spero Therapeutics, Inc. announced the Company's fourth quarter and full year 2021 financial results. In the press release, Spero disclosed that "[t]he U.S. Food and Drug Administration (FDA) has notified Spero that, as part of its ongoing review of Spero's New Drug Application (NDA) for tebipenem HBr, it has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time."
Then on May 3, 2022, Spero Therapeutics, Inc. announced "that it will immediately defer current commercialization activities for tebipenem HBr based on feedback from a recent Late Cycle Meeting with the U.S. Food and Drug Administration (FDA) regarding Spero's New Drug Application (NDA) for tebipenem HBr[,]" and that, "[a]lthough the review is still ongoing and the FDA has not yet made any final determination regarding approvability, the discussion suggested that the data package may be insufficient to support approval during this review cycle." Specifically, the FDA advised the Company, in relevant part, that the FDA's separate analysis of the relevant study population had "reduce[d] the number of evaluable patients in the primary analysis population compared with those resulting from the trial's pre-specified micro-ITT population as outlined in the statistical analysis plan and [a]s a result, the FDA considers that the pre-specified non-inferiority margin of -12.5% was not met." Further, the press release advised that, "[i]n connection with this development, Spero announced that it is undertaking a reduction in its workforce by approximately 75% and a restructuring of its operations to reduce operating costs and reallocate resources."
Shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) declined from $19.87 on September 28, 2021, to as low as $1.03 per share on June 2, 2022.
The plaintiff claims that between October 28, 2021 and May 2, 2022, the Defendants made false and/or misleading statements and/or failed to disclose that the data submitted in support of the Tebipenem HBr NDA were insufficient to obtain FDA approval, that accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form, that the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
                     Copy
                  
                 Please set a link in the press area of your homepage to this press release on openPR.  openPR disclaims liability for any content contained in this release. 
    You can edit or delete your press release Lawsuit filed for Investors in shares of Spero Therapeutics, Inc. (NASDAQ: SPRO) here
News-ID: 2644049 • Views: …
More Releases from Shareholders Foundation
 
                                            
                                                    Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE:  …                                                
                                            
                                        
                                            An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…  
                                        
                                     
                                            
                                                    Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …                                                
                                            
                                        
                                            An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. 
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…  
                                        
                                     
                                            
                                                    Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …                                                
                                            
                                        
                                            An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…  
                                        
                                     
                                            
                                                    Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025                                                
                                            
                                        
                                            A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. 
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…  
                                        
                                    More Releases for Spero
                                                    Bria Block's Journey to Healing and Pain Management at The Spero Clinic                                                
                                            
                                        
                                            Image: https://www.globalnewslines.com/uploads/2025/05/d0d212d3a14f3efe7645e371b73be890.jpg
It has been said that, among the many chronic pain disorders, Complex Regional Pain Syndrome [https://www.thesperoclinic.com/conditions/complex-regional-pain-syndrome/] (CRPS) is probably the most brutal one. Often referred to as the "suicide disease," more than 200,000 people in this country suffer from CRPS which, according to the medical community, cannot be cured.
This was the case with 29-year-old Bria Block of Lynden, WA, who has battled with CPRS since she was 11 years…  
                                        
                                    
                                                    A New Chapter: The Spero Clinic Helps CRPS Patient Lou Reclaim Her Life                                                
                                            
                                        
                                            CRPS is causing constant, debilitating pain for people around the world. Here's what The Spero Clinic is doing to save lives from this dreadful disease.
Image: https://www.globalnewslines.com/uploads/2025/02/a3269782b20b4832d25263680ae9bac8.jpg
"I had absolute plans to kill myself because I just thought this is not a life that I want."
Statements such as these sound alarming, but the truth is that many patients suffering from Complex Regional Pain Syndrome (CRPS) end up feeling this way. Why?
Because CRPS,…  
                                        
                                    
                                                    Paula's Journey: CRPS Survivor Finds Hope and Healing at the Spero Clinic                                                
                                            
                                        
                                            Paula, a survivor of Complex Regional Pain Syndrome (CRPS), shares her transformative journey toward healing at The Spero Clinic. CRPS is a chronic pain condition affecting millions, often triggered by an injury or medical event, causing severe pain, muscle spasms, and mobility issues.
Image: https://www.globalnewslines.com/uploads/2025/02/2ce8be74be632434741ecf707cfafe58.jpg
CRPS, or Complex Regional Pain Syndrome, is a chronic pain condition that affects between 5 and 8 million people around the world. CRPS [https://www.thesperoclinic.com/conditions/complex-regional-pain-syndrome/] is often triggered…  
                                        
                                    
                                                    Spero Clinic's Groundbreaking Approach to Holistic Care Transforms Lives                                                
                                            
                                        
                                            The Spero Clinic is revolutionizing the treatment of chronic pain through a holistic, patient-centered approach. Specializing in conditions like Ehlers-Danlos Syndrome (EDS), Long COVID, Fibromyalgia, and Complex Regional Pain Syndrome (CRPS), the clinic offers innovative, non-invasive treatments that address the root causes of pain, combining neurology, nutrition, physical therapy, and cutting-edge rehabilitation techniques. 
Image: https://www.getnews.info/uploads/3465313aea4cfa9a562fe1175674537d.jpg
Chronic pain affects millions of individuals worldwide, often leaving them feeling hopeless and isolated. The Spero…  
                                        
                                    
                                                    Spero Clinic at the Forefront of Chronic Disease Treatment                                                
                                            
                                        
                                            Millions in the US struggle with chronic illnesses, finding limited relief in traditional medicine. The Spero Clinic, led by Dr. Katinka van der Merwe, offers a unique approach focused on healing the root cause. 
Image: https://www.getnews.info/uploads/a2b182d267947e0da298fc8d5438ca2f.jpg
In the United States alone, an estimated 129 million people are living with a major chronic disease or illness. While these numbers are alarming, there are fortunately many healthcare providers and holistic clinics taking the…  
                                        
                                    
                                                    Carbapenem Market Key Players | Spero Therapeutics Inc., Savior Lifetec Corporat …                                                
                                            
                                        
                                            Key Highlights:
•	The global Carbapenem Market size was valued at USD 4.2 billion in 2022 growing at a CAGR of 4.5% from 2023 to 2033.
•	North America dominated the market in 2022
•	Asia Pacific is expected to grow at the highest CAGR from 2023 to 2033
As per the study initiated by Evolve Business Intelligence, the global Carbapenem Market size accounted for USD 4.2 Billion in 2022, growing at a CAGR of 4.5% from…  
                                        
                                    